Search Medical Condition
Please enter condition
Please choose location from dropdown

Yangzhou, China Clinical Trials

A listing of Yangzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (29) clinical trials

China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

Within the 12 months of the study procedure, the 3rd month is what we called the "check point". At this point, participants' plasma LDL-C will be measured whether it reached individual standard or not. If the results didn't meet the particular LDL-C standard, the participants would be adjusted the drug ...

Phase

2.04 miles

Learn More »

Stroke Imaging Package Study of Intracranial Atherosclerosis ( SIPS-ICAS )

First-ever stroke patients attributed to intracranial artery stenosis (> 50%) within 7 days after onset will be prospectively enrolled in our study and undergo new imaging technique package assessment at baseline. The imaging technique package includes conventional cranial MRI T1,T2,T2 FLAIR,DWI, and ADC), cranial magnetic resonance angiography (MRA), intracranial vessel ...

Phase N/A

2.04 miles

Learn More »

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases

This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced NSCLC with CNS metastases. Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-nave advanced NSCLC and documented intracranial disease ...

Phase

2.04 miles

Learn More »

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

Approximately 360 patients will be randomized in a 2:1 to receive treatment with durvalumab or placebo therapy. EGFR or ALK mutation randomised will be capped at approximately 15%. The primary objective of this study is to assess the efficacy of durvalumab treatment compared with placebo in terms of PFS(according to ...

Phase

2.04 miles

Learn More »

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

The maximum study duration per patient will be approximately 33 weeks: an up to 2-week screening period (it can be exceptionally extended up to one additional week), a 30-week, open label randomized treatment period comparing iGlarLixi to insulin glargine ( metformin for both treatments), and a 3-day post-treatment safety follow-up ...

Phase

2.04 miles

Learn More »

Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase

2.04 miles

Learn More »

Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer

This is a double-blind, placebo controlled, randomized multicenter global phase 3 study comparing the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in subjects with advanced gastric cancer who have responded to first line platinum based chemotherapy. Subjects are randomized 1:1 ...

Phase

2.04 miles

Learn More »

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without ...

Phase

2.04 miles

Learn More »

Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer?

Skeletal is a common metastatic site in patients with non-small cell lung cancer. The incidence of bone metastases is about 20-30 in NSCLC patients. According to the NCCN guidelines, early lung cancer patients should also undergo bone scan or PETCT before surgery to determine the presence of bone metastases. However, ...

Phase N/A

8.65 miles

Learn More »